US Pharmaceuticals Ishares ETF (IHE)

Eli Lilly has outperformed the broader market and its peers this year, and Wall Street analysts are bullish about the stock’s prospects.

Johnson & Johnson has struggled to keep up with the broader market over the past year, and analysts are cautiously bullish on its future potential.

Bristol-Myers has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Election Day has approached, and the polls indicate a tight race between Democratic Party candidate Kamala Harris and Republican nominee Donald Trump. Neither candidate holds a meaningful edge in enough...

Johnson & Johnson JNJ infused positive optimism for the broader healthcare sector after posting solid third-quarter 2024 earnings on Oct. 15. The world's biggest healthcare products maker continued with...

Eli Lilly has recently outperformed the general drug manufacturers industry, and analysts are highly optimistic about the stock’s prospects.

Eli Lilly has significantly outperformed the broader market over the past year, and Wall Street analysts are bullish about the stock’s prospects.

Despite Merck & Co.’s relative underperformance over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Despite Johnson & Johnson’s relative underperformance over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Viatris has underperformed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.